Husain S, Wagener M M, Singh N
Veterans Affairs Medical Center and University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15240, USA.
Emerg Infect Dis. 2001 May-Jun;7(3):375-81. doi: 10.3201/eid0703.010302.
Unique clinical characteristics and other variables influencing the outcome of Cryptococcus neoformans infection in organ transplant recipients have not been well defined. From a review of published reports, we found that C. neoformans infection was documented in 2.8% of organ transplant recipients (overall death rate 42%). The type of primary immunosuppressive agent used in transplantation influenced the predominant clinical manifestation of cryptococcosis. Patients receiving tacrolimus were significantly less likely to have central nervous system involvement (78% versus 11%, p =0.001) and more likely to have skin, soft-tissue, and osteoarticular involvement (66% versus 21%, p = 0.006) than patients receiving nontacrolimus- based immunosuppression. Renal failure at admission was the only independently significant predictor of death in these patients (odds ratio 16.4, 95% CI 1.9-143, p = 0.004). Hypotheses based on these data may elucidate the pathogenesis and may ultimately guide the management of C. neoformans infection in organ transplant recipients.
器官移植受者新型隐球菌感染的独特临床特征及影响其预后的其他变量尚未得到明确界定。通过对已发表报告的回顾,我们发现2.8%的器官移植受者发生了新型隐球菌感染(总体死亡率为42%)。移植中使用的主要免疫抑制剂类型影响了隐球菌病的主要临床表现。与接受非他克莫司免疫抑制的患者相比,接受他克莫司的患者发生中枢神经系统受累的可能性显著降低(78%对11%,p = 0.001),而发生皮肤、软组织和骨关节炎受累的可能性更高(66%对21%,p = 0.006)。入院时的肾衰竭是这些患者死亡的唯一独立显著预测因素(比值比16.4,95%可信区间1.9 - 143,p = 0.004)。基于这些数据的假设可能会阐明发病机制,并最终指导器官移植受者新型隐球菌感染的管理。